This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Thrombolysis  • Cardiovascular System  • World Health  • Quality of Care  • Patient Safety/ Medical Error  • Drug Therapy  • Adverse Effects  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2008;299(20):2379.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The US Food and Drug Administration (FDA) has found that the Chinese manufacturer of an ingredient in recently recalled lots of heparin products failed to follow adequate safety measures, according to a warning letter sent to the company in April.

The letter was sent to Changzhou SPL Company, Ltd, which made an ingredient used in the production of heparin products made by Baxter International of Deerfield, Ill. In the letter (http://www.fda.gov/cder/warn/2008/320-08-01.pdf), the agency notes that Changzhou failed to follow good manufacturing practices that would prevent contamination; the company had inadequate processes for removing impurities, a lack of verified testing for the products' suitability for use, and unclean equipment. The FDA also said the company had inadequate systems in place to ensure the quality of raw ingredients from outside suppliers. In some cases, materials were used that came from suppliers Changzhou had deemed unsuitable, the agency . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?